Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

2006143 citationsJournal Article

Authors

Erin R. Gardner · University of Antwerp

Henry Burger · University of Antwerp

R VANSCHAIK · University of Antwerp

A.T. VanOosterom · University of Antwerp

E A DeBruijn · University of Antwerp

G. Guetens · University of Antwerp

Hans Prenen ·

Abstract

This study indicates that common genetic variants in the evaluated genes have only a limited impact on the pharmacokinetics of imatinib. Further investigation is required to quantitatively assess the clinical significance of homozygous variant ABCG2 and CYP2D6 genotypes in patients treated with imatinib.

Topics & Keywords

Chronic Myeloid Leukemia Treatments Gastrointestinal Tumor Research and Treatment Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Pharmacology & Therapeutics

Volume 80, Issue 2, pp. 192-201

DOI: 10.1016/j.clpt.2006.05.003

Field-Weighted Citation Impact: 6.34